Meloxicam tab 15mg 20 pcs vertex


Meloxicam tab 15mg 20 pcs vertex


SKU: 1107264831 Categories: , , Tags: ,


Active substance:
1 tablet contains: meloxicam – 7.5 mg ili15 ;.
Lactose (milk sugar), microcrystalline cellulose, sodium citrate dihydrate, povidone (polyvinylpyrrolidone), sodium carboxymethyl starch (Primogel), colloidal silica (Aerosil), calcium stearate.
Tablets from light yellow to yellow color, Valium forms a chamfer. Tablets dosed at 15 mg have the risk on the one hand. Presence of marbling and minor inclusions.
Product form:
Tablets of 7.5 mg and 15 mg.
At 10 or 20 tablets in blisters. 10 or 20 tablets per polymer jar. 1 or 2 blisters with 10 tablets, or 1 blisters 20 tablets or Bank 1 together with instructions for use in a stack of cardboard.
– Hypersensitivity to any component of the drug; – anamnestic data fit bronchial, rhinitis, urticaria, after receiving aspirin or other NSAIDs (complete or incomplete syndrome intolerance of acetylsalicylic acid – rhinosinusitis, urticaria, polyps, nasal mucosa, asthma (bronchial)); – erosive and ulcerative changes in gastric mucosa and 12 duodenal ulcer, active gastrointestinal bleeding; – inflammatory bowel disease (ulcerative colitis, Crohn’s disease); – cerebrovascular bleeding or other bleeding; contraindicated in the post-coronary artery bypass surgery; – decompensated heart failure; – severe hepatic failure or active liver disease; severe renal failure in patients not undergoing dialysis (creatinine clearance less than 30 mL / min), progressive renal disease including confirmed by hyperkalemia; – pregnancy, breast-feeding; – Children up to age 15 years.
Precautions: coronary heart disease, cerebrovascular disease, chronic heart failure (CHF), dyslipidemia / hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, creatinine clearance less than 60 mL / min. A history of the development of ulcerative lesions gastrointestinal tract, for infections of Helicobacter pylori, old age, long-term use of NSAIDs, frequent alcohol consumption, severe somatic diseases, concomitant therapy with the following drugs:
– anticoagulant (e.g., warfarin);
– antiplatelet agents (e.g., aspirin, clopidogrel);
– oral corticosteroids (e.g., prednisone);
selective serotonin reuptake inhibitors (e.g., citalopram, fluoxetine, paroxetine, sertraline).
To reduce the risk of adverse effects on the gastrointestinal tract should use the lowest effective dose of the lowest possible short course.
Symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (Bechterew’s disease) and other inflammatory and degenerative diseases accompanied by pain.
Interaction with other drugs
– With simultaneous use of other nonsteroidal anti-inflammatory drugs (and also with acetylsalicylic acid) increases the risk of erosive ulcers and gastrointestinal bleeding; – While the use of antihypertensive drugs may decrease the effectiveness of the latter; – In an application with lithium preparations may develop lithium accumulation and increase its toxic effect (recommended control the concentration of lithium in the blood); – With simultaneous use with methotrexate amplified side effects of the latter on the hematopoietic system (risk of anemia and leukopenia shown periodic blood count control); – the simultaneous use of diuretics and cyclosporine increases the risk of kidney failure; – While the use of intrauterine contraceptive devices may reduce the effectiveness of the latter; – the simultaneous use of anticoagulants (heparin, ticlopidine, warfarin), as well as with thrombolytic drugs (streptokinase, fibrinolizin) increases the risk of bleeding (requires periodic monitoring of indicators of blood clotting); – Together with the application kolestiraminom, as a result of binding of meloxicam, increasing its excretion via the gastrointestinal tract.
Symptoms: violation of consciousness, nausea, vomiting, pain in epigastralii, ZHKT- bleeding, acute renal failure, liver failure, respiratory arrest, asystole.
Treatment: No specific antidote; with an overdose of the drug should be to gastric lavage, administration of activated charcoal (during the next hour), symptomatic therapy. Cholestyramine accelerates the excretion of the drug. Forced diuresis, urinary alkalization, hemodialysis – are ineffective due to high drug connection with blood proteins.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug.
Meloxicam – a non-steroidal anti-inflammatory drug having analgesic, antiinflammatory and antipyretic action. The anti-inflammatory action due to inhibition of the enzymatic activity of cyclooxygenase-2 (COX-2) involved in the biosynthesis of prostaglandins in inflammation. To a lesser extent meloxicam acts on cyclooxygenase-1 (COX-1) involved in prostaglandin synthesis, protecting the mucosa of the gastrointestinal tract and participate in the regulation of renal blood flow.
Well absorbed from the gastrointestinal tract, the absolute bioavailability of meloxicam – 89%. Simultaneous food intake does not modify absorption. When using the drug orally at doses of 7.5 and 15 mg doses are proportional to its concentration. The equilibrium concentration is reached within 3-5 days. With prolonged use of drugs (for more than 1 year), a concentration similar to those that have been observed after the first reaching the equilibrium state. Plasma protein binding is 99%. The range differences between the maximum and basal concentrations of the drug after administration once a day is relatively small and is at a dose of 7.5 mg 0.4-1.0 g / ml, and at a dose of 15 mg – 08-2,0 mcg / ml (respectively shown Cmix and Cmax values). Meloxicam penetrates the blood-tissue barriers, concentrations in synovial fluid reaches 50% of the maximum drug concentration in plasma.
Metabiliziruetsya almost entirely in the liver to form four pharmacologically inactive derivatives. The main metabolite, 5-carboxy- meloxicam (60% of the dose), formed by oxidation of an intermediate metabolite 5′-gidroksimetilmeloksikama which is also excreted, but to a lesser extent (9% of the dose). Studies in vitro have shown that in this metabolic conversion plays an important role CYP 2C9, additional importance ZA4 CYP isozyme. The formation of two other metabolites (representing respectively 16% and 4% of the dose) participates peroxidase, which activity is likely to vary individually. Derived equally from feces and urine, mainly as metabolites. Since feces unchanged output of less than 5% of the daily dose in the urine as unchanged drug is detected only in trace amounts. The half-life (T1 / 2) of meloxicam is 15-20 hours. Plasma clearance is an average of 8 ml / min. In the elderly the clearance of the drug is reduced. The volume of distribution is low and an average of 11 liters. Hepatic or renal failure moderate no significant effect on the pharmacokinetics of meloxicam.
Pregnancy and breast-feeding
The drug is not recommended for use during pregnancy and lactation.
Conditions of supply of pharmacies
side effects
From the digestive system: more than 1% – indigestion, including nausea, vomiting, W abdominal pain, constipation, flatulence, diarrhea; 0.1 – 1% – transient increase in “liver” enzymes, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, bleeding from the gastrointestinal tract (including hidden), stomatitis; less than 0.1% – perforation of the gastrointestinal tract, colitis, hepatitis, gastritis.
From the side of hematopoiesis: more than 1% – anemia; 0.1 – 1% – changes in blood counts, including leukopenia, thrombocytopenia.
For the skin: more than 1% – itching, skin rash; 0.1-1% urticaria; less than 0.1% – photosensitivity, bullous eruptions, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis.
The respiratory system: less than 0.1% – bronchospasm.
From the nervous system, more than 1% – dizziness, headache; 0.1 – 1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.
Cardio-vascular system, more than 1% – peripheral edema; 0.1-1% – increase in blood pressure, palpitations, “tides” of blood to the skin.
From the urinary system. 0.1 – 1% – hypercreatininemia and / or an increase in serum urea; less than 0.1% – acute renal failure; connection with the intake of meloxicam is not installed – interstitial nephritis, albuminuria, hematuria.
From the senses: less than 0.1% – conjunctivitis, impaired vision, including blurred vision.
Allergic reactions: less than 0.1% – angioedema, anaphylactoid / anaphylactic reactions.
special instructions
Caution should be exercised when using the drug in patients with a history in which the gastric ulcer or duodenal ulcer, as well as in patients on anticoagulant therapy. In these patients, increased risk of erosive and ulcerative diseases of the gastrointestinal tract. Care should be taken to monitor renal function when using the drug in elderly patients, patients with chronic heart failure with inadequate circulation phenomena in patients with cirrhosis, and in patients with hypovolemia resulting from surgical procedures. – Patients with renal failure if creatinine clearance greater than 25 mL / min is required dosing regime correction. – Patients on dialysis, drug dosage should not exceed 7.5 mg / day. – Patients taking both diuretics and meloxicam, should take plenty of fluids. – If during treatment with any allergic reactions (itching, skin rash, urticaria, photosensitivity) should stop taking the drug and consult a doctor.
Effects on ability to transp. Wed. and fur. : Application of the drug can cause undesired effects as headache and dizziness, sleepiness. Should abandon the vehicle management and maintenance of machines and mechanisms that require concentration.
Storage conditions
In the dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
The drug is taken orally during meal time every day.
The recommended dosing regimen: – rheumatoid arthritis: 15 mg per day. After achieving a therapeutic effect, the dose can be reduced to 7.5 mg per day. – Osteoarthritis: 7.5 mg. If necessary, the dose may be increased to 15 mg per day. – Ankylosing spondylitis: 15 mg per day.
The maximum daily dose should not exceed 15 mg.
In patients with an increased risk of side effects, as well as in patients with advanced renal failure on hemodialysis, the dose should not exceed 7.5 mg per day.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review